<DOC>
	<DOCNO>NCT00001036</DOCNO>
	<brief_summary>To determine safety thymosin alpha 1 give twice weekly regimen daily oral zidovudine ( AZT ) biweekly polyethylene glycolated interleukin-2 ( PEG IL-2 ) . To determine effect thymosin alpha 1 PEG IL-2 combination AZT immunologic pharmacokinetic marker . AIDS characterize diminish T helper cell number function . Thymosin alpha 1 appear increase IL-2 receptor lymphocytes vitro enhance lymphocyte maturation vivo ; thus , drug may enhance CD4 T cell level patient receive AZT PEG IL-2 .</brief_summary>
	<brief_title>The Safety Effectiveness Type Interleukin-2 Plus Zidovudine Plus Thymosin HIV-Positive Patients With Without Symptoms Infection</brief_title>
	<detailed_description>AIDS characterize diminish T helper cell number function . Thymosin alpha 1 appear increase IL-2 receptor lymphocytes vitro enhance lymphocyte maturation vivo ; thus , drug may enhance CD4 T cell level patient receive AZT PEG IL-2 . Patients stabilized oral AZT daily 8 week begin receive bolus infusion PEG IL-2 every week least four dos . Thymosin alpha 1 ( give SC ) add regimen twice weekly 4 week . If significant toxicity occur , thymosin alpha 1 increase administer along schedule dos PEG IL-2 additional 8 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylactic pentamidine Pneumocystis carinii . Patients must : HIV seropositivity . CD4 count &gt; 50 &lt; 200 cells/mm3 . No active opportunistic infection . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Concurrent neoplasm basal cell carcinoma skin , situ carcinoma cervix , Kaposi 's sarcoma . Significant cardiac disease CNS lesions neurologic abnormality . Score &gt; 0.5 ACTG AIDS Dementia Complex staging . Major organ allograft . Intolerance AZT 500 mg/day . Concurrent Medication : Excluded : Antihypertensive medication diuretic . Chemotherapy , hormonal therapy , immunotherapy . Other investigational drug , agent , device . Betablockers . Nontopical steroid . Concurrent Treatment : Excluded : Radiation therapy . Prior Medication : Excluded : Known antiHIV medication ( AZT ) know immunomodulators ( e.g. , systemic steroid , interferon , interleukin ) chemotherapy within 30 day prior study entry . Prior Treatment : Excluded : Transfusion within 4 week prior study entry . Radiation within 30 day prior study entry . Active substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1996</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Polyethylene Glycols</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Adjuvants , Immunologic</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>thymosin alpha ( 1 )</keyword>
</DOC>